Cargando…
Neuro-ophthalmologic outcomes of standard versus hypo-fractionated stereotactic radiotherapy of AVPM
BACKGROUND: Most anterior visual pathway meningiomas (AVPM) are benign and slow-growing, but these tumors may affect visual functions, including visual acuity (VA) and visual field (VF). Due to location, most are treated non-surgically by fractionated stereotactic radiotherapy (FSRT), aiming to prev...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403384/ https://www.ncbi.nlm.nih.gov/pubmed/34454551 http://dx.doi.org/10.1186/s13014-021-01879-2 |
_version_ | 1783745989340823552 |
---|---|
author | Zach, Leor Agami, Amir Furman, Orit Attia, Moshe Cohen, Zvi Mizrachi, Iris Ben-Bassat Tam, Guy Zibly, Zion Nissim, Ouzi Spiegelmann, Roberto Huna-Baron, Ruth |
author_facet | Zach, Leor Agami, Amir Furman, Orit Attia, Moshe Cohen, Zvi Mizrachi, Iris Ben-Bassat Tam, Guy Zibly, Zion Nissim, Ouzi Spiegelmann, Roberto Huna-Baron, Ruth |
author_sort | Zach, Leor |
collection | PubMed |
description | BACKGROUND: Most anterior visual pathway meningiomas (AVPM) are benign and slow-growing, but these tumors may affect visual functions, including visual acuity (VA) and visual field (VF). Due to location, most are treated non-surgically by fractionated stereotactic radiotherapy (FSRT), aiming to prevent tumor progression and visual functions deterioration. Unfortunately, FSRT in itself may affect visual functions. The current preferred treatment regimen (in terms of safety and effectiveness) is undetermined. While most cases are treated with conventional fractionation (cFSRT)—50.4–54 Gy in 28–30 fractions of 1.8–2 Gy, advances in technology have allowed shortening of total treatment length to hypofractionation (hSRT)—25-27 Gy in 3–5 fractions of 5–9 Gy. Our aim was to evaluate the association of radiotherapy regimen for treating AVPM (cFSRT vs. hSRT) with visual function outcomes (VA, VF) at the last neuro-ophthalmologic evaluation. METHODS: We conducted a retrospective cohort study of AVPM cases treated at Sheba Medical Center during 2004–2015. We compared cFSRT and hSRT regimens regarding visual function (VA, VF) outcomes at the last neuro-ophthalmologic evaluation. VA was determined by the logarithm of the minimum angle of resolution (LogMAR). VF was determined by the mean deviation (MD). A clinically relevant change in VA was defined as 0.2 LogMAR. RESULTS: 48 patients (13 receiving hSRT, 35 receiving cFSRT) were included, with a median follow-up of 55 months. No significant difference was evident regarding LogMAR or MD of involved eyes at the last evaluation. Six (17%) patients in the cFSRT group experienced clinically relevant VA deterioration in the involved eye, compared with six (46%) in hSRT (p = 0.06). CONCLUSION: Our findings, using comprehensive and meticulous investigation of visual outcomes, suggest that hSRT may be associated with higher risk for VA and VF deterioration in AVPM especially in ONSM. We recommend the use of cFSRT for ONSM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13014-021-01879-2. |
format | Online Article Text |
id | pubmed-8403384 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84033842021-08-30 Neuro-ophthalmologic outcomes of standard versus hypo-fractionated stereotactic radiotherapy of AVPM Zach, Leor Agami, Amir Furman, Orit Attia, Moshe Cohen, Zvi Mizrachi, Iris Ben-Bassat Tam, Guy Zibly, Zion Nissim, Ouzi Spiegelmann, Roberto Huna-Baron, Ruth Radiat Oncol Research BACKGROUND: Most anterior visual pathway meningiomas (AVPM) are benign and slow-growing, but these tumors may affect visual functions, including visual acuity (VA) and visual field (VF). Due to location, most are treated non-surgically by fractionated stereotactic radiotherapy (FSRT), aiming to prevent tumor progression and visual functions deterioration. Unfortunately, FSRT in itself may affect visual functions. The current preferred treatment regimen (in terms of safety and effectiveness) is undetermined. While most cases are treated with conventional fractionation (cFSRT)—50.4–54 Gy in 28–30 fractions of 1.8–2 Gy, advances in technology have allowed shortening of total treatment length to hypofractionation (hSRT)—25-27 Gy in 3–5 fractions of 5–9 Gy. Our aim was to evaluate the association of radiotherapy regimen for treating AVPM (cFSRT vs. hSRT) with visual function outcomes (VA, VF) at the last neuro-ophthalmologic evaluation. METHODS: We conducted a retrospective cohort study of AVPM cases treated at Sheba Medical Center during 2004–2015. We compared cFSRT and hSRT regimens regarding visual function (VA, VF) outcomes at the last neuro-ophthalmologic evaluation. VA was determined by the logarithm of the minimum angle of resolution (LogMAR). VF was determined by the mean deviation (MD). A clinically relevant change in VA was defined as 0.2 LogMAR. RESULTS: 48 patients (13 receiving hSRT, 35 receiving cFSRT) were included, with a median follow-up of 55 months. No significant difference was evident regarding LogMAR or MD of involved eyes at the last evaluation. Six (17%) patients in the cFSRT group experienced clinically relevant VA deterioration in the involved eye, compared with six (46%) in hSRT (p = 0.06). CONCLUSION: Our findings, using comprehensive and meticulous investigation of visual outcomes, suggest that hSRT may be associated with higher risk for VA and VF deterioration in AVPM especially in ONSM. We recommend the use of cFSRT for ONSM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13014-021-01879-2. BioMed Central 2021-08-28 /pmc/articles/PMC8403384/ /pubmed/34454551 http://dx.doi.org/10.1186/s13014-021-01879-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Zach, Leor Agami, Amir Furman, Orit Attia, Moshe Cohen, Zvi Mizrachi, Iris Ben-Bassat Tam, Guy Zibly, Zion Nissim, Ouzi Spiegelmann, Roberto Huna-Baron, Ruth Neuro-ophthalmologic outcomes of standard versus hypo-fractionated stereotactic radiotherapy of AVPM |
title | Neuro-ophthalmologic outcomes of standard versus hypo-fractionated stereotactic radiotherapy of AVPM |
title_full | Neuro-ophthalmologic outcomes of standard versus hypo-fractionated stereotactic radiotherapy of AVPM |
title_fullStr | Neuro-ophthalmologic outcomes of standard versus hypo-fractionated stereotactic radiotherapy of AVPM |
title_full_unstemmed | Neuro-ophthalmologic outcomes of standard versus hypo-fractionated stereotactic radiotherapy of AVPM |
title_short | Neuro-ophthalmologic outcomes of standard versus hypo-fractionated stereotactic radiotherapy of AVPM |
title_sort | neuro-ophthalmologic outcomes of standard versus hypo-fractionated stereotactic radiotherapy of avpm |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403384/ https://www.ncbi.nlm.nih.gov/pubmed/34454551 http://dx.doi.org/10.1186/s13014-021-01879-2 |
work_keys_str_mv | AT zachleor neuroophthalmologicoutcomesofstandardversushypofractionatedstereotacticradiotherapyofavpm AT agamiamir neuroophthalmologicoutcomesofstandardversushypofractionatedstereotacticradiotherapyofavpm AT furmanorit neuroophthalmologicoutcomesofstandardversushypofractionatedstereotacticradiotherapyofavpm AT attiamoshe neuroophthalmologicoutcomesofstandardversushypofractionatedstereotacticradiotherapyofavpm AT cohenzvi neuroophthalmologicoutcomesofstandardversushypofractionatedstereotacticradiotherapyofavpm AT mizrachiirisbenbassat neuroophthalmologicoutcomesofstandardversushypofractionatedstereotacticradiotherapyofavpm AT tamguy neuroophthalmologicoutcomesofstandardversushypofractionatedstereotacticradiotherapyofavpm AT ziblyzion neuroophthalmologicoutcomesofstandardversushypofractionatedstereotacticradiotherapyofavpm AT nissimouzi neuroophthalmologicoutcomesofstandardversushypofractionatedstereotacticradiotherapyofavpm AT spiegelmannroberto neuroophthalmologicoutcomesofstandardversushypofractionatedstereotacticradiotherapyofavpm AT hunabaronruth neuroophthalmologicoutcomesofstandardversushypofractionatedstereotacticradiotherapyofavpm |